Immersive Virtual Reality for Older Adults in Long-Term Care Settings (VR-LTC)
Use of Immersive Virtual Reality in Long-Term Care Facilities and Seniors' Homes in Quebec
The goal of this clinical trial is to learn if an immersive virtual reality mindfulness meditation program is feasible and acceptable for older adults living in long-term care settings in Quebec who have mild to moderate neurocognitive disorder. It will also learn about the safety and potential effects of the program on well-being.
The main questions it aims to answer are:
- Is the virtual reality mindfulness meditation program feasible and acceptable for residents and staff in long-term care settings?
- Does the adapted version of the program show potential benefits for well-being, including depression, anxiety, quality of life, mindfulness, pain, and loneliness?
- What practical challenges, user experiences, and side effects, such as cybersickness, occur during the program?
Researchers will compare the original Toujours Dimanche virtual reality mindfulness meditation program, an adapted version of Toujours Dimanche designed for older adults with mild to moderate neurocognitive disorder, and standard care alone to see if the adapted program is feasible, acceptable, and potentially helpful.
Participants will:
- Take part in up to 8 virtual reality mindfulness meditation sessions over 4 weeks, if assigned to a virtual reality group
- Complete questionnaires before and after the 4-week study period
- Share feedback about their experience, when possible
- Be observed by staff or research team members to document feasibility, acceptability, user experience, and safety
Panoramica dello studio
Stato
Descrizione dettagliata
This pilot feasibility trial will evaluate the use of a mindfulness meditation intervention delivered with or without the Toujours Dimanche immersive virtual reality application in long-term care settings in Quebec. The study will be conducted with older adults living in long-term care facilities, seniors' homes, and alternative seniors' homes in the Chaudière-Appalaches and Capitale-Nationale regions who have mild to moderate cognitive impairment or neurocognitive disorder.
The pilot phase will use a randomized experimental design. The purpose of this phase is to evaluate the feasibility, acceptability, safety, user experience, and preliminary effects of the intervention in real-world long-term care settings. This phase will also help identify practical issues related to time management, human resources, data collection, and intervention delivery before a future larger-scale effectiveness trial.
A total of 36 residents will be recruited. This sample size is based on recommendations for feasibility studies, with 12 participants per group. Staff members who regularly work with participating residents and who have completed virtual reality training through Super Splendide and/or Martine Bordeleau will also be recruited. These staff members will deliver the intervention and provide feedback on its feasibility and acceptability.
Residents who meet the inclusion and exclusion criteria will be assigned to one of three groups. Group A will receive standard care and guided mindfulness meditation sessions designed for people with cognitive impairment. Group B will receive standard care and the adapted version of the Toujours Dimanche program, which includes guided mindfulness meditation sessions designed for people with cognitive impairment. Group C will receive standard care for four weeks.
Allocation to the groups will be performed using minimization, a method recognized as an acceptable alternative to randomization when the sample size is small. The allocation procedure will consider sex, gender, and age group. The study coordinator will have access to participants' group allocation. The long-term care team will plan the intervention sessions and inform the study coordinator of the selected dates and times.
Participants in Groups A and B will be invited to complete 8 mindfulness meditation sessions over 4 consecutive weeks, with approximately 2 sessions per week. Each session will last about 5 to 15 minutes, depending on the participant's preferences, comfort, and tolerance. The sessions will be delivered by trained staff members who know the participating residents well. Sessions will take place in the resident's room. Participants may stop a session at any time.
Data will be collected from residents and staff members when possible. If a resident has difficulty communicating verbally or through gestures, the staff member who knows the resident best may provide responses using observer-rated versions of the questionnaires. Sociodemographic information will be collected at baseline. Feedback on the program will be collected after the 4-week study period from residents, when possible, and from staff members.
Feasibility outcomes will include recruitment, adherence, attrition, intervention completion, and practical challenges encountered during implementation. Acceptability will be assessed from the perspectives of residents and staff using researcher-developed questions, including visual analogue scales and open-ended questions. User experience, perceived presence, potential risks, side effects, and other practical issues will also be documented.
Preliminary clinical outcomes will be assessed before the beginning of the intervention and after the end of the 4-week period. The primary clinical outcomes are depression and anxiety. Quality of life will be assessed as a secondary outcome. Mindfulness, pain, and loneliness will be assessed as tertiary or exploratory outcomes. Measures will be administered in a predefined order, beginning with depression and anxiety, followed by quality of life, and then the exploratory outcomes. If a participant shows signs of excessive fatigue or reduced motivation, data collection may be paused or stopped.
Because the study includes residents with cognitive impairment, consent and assent procedures will be adapted to protect residents' rights, comfort, and dignity. When residents are able to provide informed consent, consent will be obtained directly from them. When needed, consent will be obtained from a legal representative or from a person authorized to consent on behalf of the resident. Resident assent will also be sought verbally or behaviorally before participation. Before each visit, residents will be asked whether they are still interested in participating. If a resident refuses, shows distress, or no longer wishes to participate, study activities will stop.
The purpose of this pilot trial is not to determine definitive effectiveness. Rather, it will assess whether the intervention and study procedures are feasible, acceptable, and safe for older adults with mild to moderate cognitive impairment or neurocognitive disorder living in long-term care settings.
Tipo di studio
Iscrizione (Stimato)
Fase
- Non applicabile
Contatti e Sedi
Contatto studio
- Nome: Martine Bordeleau, PhD
- Numero di telefono: 581-490-2626
- Email: martine.bordeleau@outlook.com
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
- Adulto
- Adulto più anziano
Accetta volontari sani
Descrizione
Inclusion Criteria:
For resident participants:
- Resident of a participating long-term care facility, seniors' home, or alternative seniors' home in the Chaudière-Appalaches or Capitale-Nationale regions of Quebec
- Aged 60 years or older
- Able to understand French or English
- Able to provide informed consent or assent, or have consent provided by a legally authorized representative or person authorized to consent
- Mild to moderate cognitive impairment or neurocognitive disorder
- Normal or corrected vision and hearing
For staff participants:
- Regularly works with at least one resident participating in Phase 3
- Has completed the revised virtual reality training provided by Super Splendide and/or Martine Bordeleau
Exclusion Criteria:
For resident participants:
- Recurrent migraines
- Epilepsy
- Traumatic brain injury during the past year
- Glaucoma or recovery from eye surgery
- Diagnosed uncontrolled epilepsy
- Diagnosed severe vertigo
- Severe hearing impairment without a corrective hearing device
- Significant visual impairment that would prevent use of a virtual reality headset
- Motion sickness that would prevent use of a virtual reality headset
- Any health condition that restricts movement or prevents safe participation, such as a significant reduction in neck or upper-limb range of motion
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Terapia di supporto
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: Guided Mindfulness Meditation
Participants in this group will receive standard care and guided mindfulness meditation sessions designed for people with cognitive impairment.
Participants will be invited to complete 8 sessions over 4 consecutive weeks, with approximately 2 sessions per week.
Each session will last about 5 to 15 minutes, depending on participant preferences, comfort, and tolerance.
|
Mindfulness Meditation for Cognitive Impairment
Standard Care
|
|
Sperimentale: Adapted Toujours Dimanche Virtual Reality Meditation
Participants in this group will receive standard care and the adapted Toujours Dimanche immersive virtual reality program.
The intervention includes guided mindfulness meditation sessions designed for older adults with mild to moderate cognitive impairment or neurocognitive disorder.
Participants will be invited to complete 8 sessions over 4 consecutive weeks, with approximately 2 sessions per week.
Each session will last about 5 to 15 minutes.
|
Standard Care
Immersive Virtual Reality Mindfulness Meditation
|
|
Comparatore attivo: Standard Care
Participants in this group will receive standard care alone for 4 weeks.
They will not receive the guided mindfulness meditation intervention or the Toujours Dimanche virtual reality meditation program during the study period.
|
Standard Care
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Recruitment, Retention, Adherence, Blinding, and Safety Feasibility Indicators
Lasso di tempo: Up to 4 weeks
|
Feasibility will be assessed descriptively using feasibility indicators recommended by Thabane et al. for pilot studies.
These indicators will include recruitment feasibility, assessed by the recruitment rate; intervention completion, assessed through adherence to planned sessions and attrition/retention rates; blinding feasibility, assessed through the effectiveness of blinding procedures; potential risks, assessed through the number, type, frequency, and severity of adverse events; and practical implementation challenges requiring modification of the intervention or study procedures.
Reference: Thabane L, Ma J, Chu R, et al.
A tutorial on pilot studies: the what, why and how.
BMC Medical Research Methodology.
2010;10(1):1-10.
|
Up to 4 weeks
|
|
Acceptability of the Intervention
Lasso di tempo: At 4 weeks
|
Acceptability will be assessed from the perspectives of residents and staff using a researcher-developed acceptability questionnaire designed specifically for this study.
The questionnaire includes 1-to-7 visual analogue scales and open-ended questions about the virtual reality mindfulness meditation program.
For the 1-to-7 scales, the minimum value is 1 and the maximum value is 7, with higher scores indicating greater acceptability of the intervention.
Open-ended responses will be summarized descriptively to document participants' and staff members' perceptions, comments, and suggestions.
|
At 4 weeks
|
|
Change in Depression Symptoms
Lasso di tempo: Baseline and 4 weeks
|
Depression symptoms will be assessed using the Patient Health Questionnaire-9 (PHQ-9), completed by the resident when possible and/or by a staff member using an observer-rated version.
Total scores range from 0 to 27.
Higher scores indicate greater depression symptom severity.
|
Baseline and 4 weeks
|
|
Change in Anxiety Symptoms
Lasso di tempo: Baseline and 4 weeks
|
Anxiety symptoms will be assessed using the Generalized Anxiety Disorder-7 item scale (GAD-7), completed by the resident when possible and/or by a staff member using an observer-rated version.
Total scores range from 0 to 21.
Higher scores indicate greater anxiety symptom severit
|
Baseline and 4 weeks
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Change in Quality of Life
Lasso di tempo: Baseline and 4 weeks
|
Quality of life will be assessed using the Quality of Life in Alzheimer's Disease Scale Nursing Home version (QoL-AD-NH), completed by the resident when possible and/or by a caregiver proxy.
The QoL-AD-NH includes 13 items assessing key life domains, such as physical health, mood, memory, relationships, and finances.
Each item is scored on a 4-point scale: 1 = poor, 2 = fair, 3 = good, and 4 = excellent.
Total scores range from 13 to 52, with higher scores indicating better quality of life.
Scores from 40 to 52 indicate high quality of life, scores from 27 to 39 indicate moderate quality of life, and scores from 13 to 26 indicate low quality of life.
|
Baseline and 4 weeks
|
Altre misure di risultato
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Change in Self-Reported Pain Intensity
Lasso di tempo: Baseline and 4 weeks
|
Self-reported pain intensity will be assessed using the Numeric Rating Scale (NRS), completed by the resident when possible.
Scores range from 0 to 10, where 0 indicates no pain and 10 indicates the worst possible pain.
Higher scores indicate greater pain intensity.
|
Baseline and 4 weeks
|
|
Change in Observed Pain
Lasso di tempo: Baseline and 4 weeks
|
Observed pain will be assessed using the Pain Assessment in Advanced Dementia Scale (PAIN-AD), completed by a staff member.
The PAIN-AD includes 5 observed behavioral indicators, each scored from 0 to 2. Total scores range from 0 to 10, with higher scores indicating more pain-related behaviors.
A score of 0 indicates no observed pain-related behavior; scores from 1 to 3 may indicate mild pain; scores from 4 to 6 may indicate moderate pain; and scores from 7 to 10 may indicate severe pain.
|
Baseline and 4 weeks
|
|
Change in Loneliness
Lasso di tempo: Baseline and 4 weeks
|
Loneliness will be assessed using the UCLA Loneliness Scale short form (ULS-6), completed by the resident when possible.
The ULS-6 includes 6 items.
Total scores range from 6 to 24, with higher scores indicating greater loneliness.
|
Baseline and 4 weeks
|
|
Change in Social Engagement
Lasso di tempo: Baseline and 4 weeks
|
Social engagement will be assessed using the Engagement of a Person with Dementia Scale (EPWDS), completed by a staff member.
The EPWDS includes 10 items assessing affective, visual, verbal, behavioral, and social engagement.
Each item is scored on a 1-to-5 scale, with some items reverse scored.
Total scores range from 10 to 50.
Higher scores indicate greater positive engagement, while lower scores indicate greater disengagement or negative engagement.
|
Baseline and 4 weeks
|
|
Change in Daily Mindful Responding
Lasso di tempo: Baseline and 4 weeks
|
Daily mindful responding will be assessed using the Daily Mindful Responding Scale (DMRS), completed by the resident when possible.
The DMRS is a 4-item scale designed to assess mindful responding in daily life.
Items are rated on a 1-to-10 scale, and item scores are averaged to compute the total score.
Total scores range from 1 to 10. Higher scores indicate greater mindful responding in daily life.
|
Baseline and 4 weeks
|
|
Change in Observed Mindfulness
Lasso di tempo: Baseline and 4 weeks
|
Observed mindfulness will be assessed using the Observed Mindfulness Measure (OMM), completed by a staff member who knows the resident.
The OMM is a 9-item observer-rated questionnaire assessing mindful behaviors, including awareness, acceptance, and attentiveness.
Total scores range from 9 to 45. Higher scores indicate greater observed mindful behavior.
|
Baseline and 4 weeks
|
Collaboratori e investigatori
Sponsor
Investigatori
- Investigatore principale: Maude Laberge, PhD, Laval University
Studiare le date dei record
Studia le date principali
Inizio studio (Stimato)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- MP-23-2024-1086
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su Guided Mindfulness Meditation
-
Johns Hopkins UniversityTerminatoLupus eritematoso sistemico | Vasculite | Artrite infiammatoria | Miosite | Sindrome di Sjogren | SclerodermiaStati Uniti
-
Equa HealthNational Institute of Mental Health (NIMH); Worcester Polytechnic InstituteReclutamentoDisagio psicologico | Abilità di consapevolezza | Soddisfazione dell'usabilitàStati Uniti
-
The University of Texas at DallasCompletatoInvecchiamento sanoStati Uniti
-
Xijing HospitalIscrizione su invito
-
Mayo ClinicAttivo, non reclutante
-
Aga Khan UniversityNon ancora reclutamento
-
Clinica Universidad de Navarra, Universidad de...Non ancora reclutamentoCancro alla prostata
-
Abbott Medical DevicesRitiratoArresto cardiacoStati Uniti
-
Aarhus University Hospital SkejbyAbbottIscrizione su invitoCardiopatia ischemica | Coronaropatia ischemica | SCA (sindrome coronarica acuta)Danimarca, Belgio, Germania, Finlandia, Svezia, Svizzera, Lettonia, Norvegia, Regno Unito, Estonia, Olanda, Italia
-
University of Alabama at BirminghamNon ancora reclutamento